SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?


To: Biomaven who wrote (232)11/22/1997 6:42:00 PM
From: Saul H Rosenthal  Respond to of 717
 
Peter, Thanks for the interesting post.

Saul



To: Biomaven who wrote (232)11/23/1997 9:38:00 AM
From: Flagrante Delictu  Respond to of 717
 
Peter, Thanks for your update on the website. I really admire your ability to select big winners. PCYC is my second largest holding also, with LGND being larger & SEPR being unfotunately significantly lesser. Good luck on your continued mastery of the market. Can you only imagine what could happen to this baby if the athero & ribosomal indications reach commercialization in addition to the cancer & other indications? Bernie.



To: Biomaven who wrote (232)11/27/1997 8:42:00 PM
From: tnsaf  Read Replies (1) | Respond to of 717
 
OFF TOPIC:
Peter, have you looked at EntreMed (ENMD)? They have gotten a lot of press the last few days from a talk given by J Folkman.

Jason



To: Biomaven who wrote (232)12/17/1997 4:15:00 PM
From: HB  Read Replies (1) | Respond to of 717
 
Anyone have any idea of the financial details of this deal?
biz.yahoo.com
(Alcon gets worldwide marketing rights to Lutryn for macular
degeneration & other opthalmologic uses.